Total Payments
$7,557
2024 Payments
$1,088
Companies
42
Transactions
410
Medicare Patients
17,676
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$6,304 (83.4%)
Travel$1,207 (16.0%)
Education$45.82 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,304 | 406 | 83.4% |
| Travel and Lodging | $1,207 | 3 | 16.0% |
| Education | $45.82 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic Vascular, Inc. | $1,637 | 13 | $0 (2019) |
| Amgen Inc. | $802.32 | 56 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $789.08 | 46 | $0 (2024) |
| PFIZER INC. | $634.56 | 60 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $523.09 | 32 | $0 (2024) |
| Merck Sharp & Dohme LLC | $393.59 | 27 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $289.32 | 20 | $0 (2024) |
| Abbott Laboratories | $286.14 | 16 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $250.36 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $213.68 | 15 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,088 | 64 | Novartis Pharmaceuticals Corporation ($247.60) |
| 2023 | $1,027 | 61 | PFIZER INC. ($162.22) |
| 2022 | $700.23 | 45 | Bayer HealthCare Pharmaceuticals Inc. ($120.98) |
| 2021 | $509.31 | 38 | Janssen Pharmaceuticals, Inc ($103.71) |
| 2020 | $177.61 | 12 | Amgen Inc. ($50.19) |
| 2019 | $559.59 | 39 | Amgen Inc. ($119.87) |
| 2018 | $2,574 | 81 | Medtronic Vascular, Inc. ($1,619) |
| 2017 | $922.04 | 70 | PFIZER INC. ($133.75) |
All Payment Transactions
410 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: DIABETES | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: DIABETES | ||||||
| 11/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Cardio-renal | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $10.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/14/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $19.74 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: DIABETES | ||||||
| 10/02/2024 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 09/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/26/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Cardio-renal | ||||||
| 08/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: DIABETES | ||||||
| 08/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/12/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: Cardio-renal | ||||||
| 08/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/01/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/29/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/22/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $20.21 | General |
| Category: Heart Failure and Hypertension | ||||||
| 07/18/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: CDS broad portfolio offering_CRM | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 3,560 | 4,587 | $735,563 | $234,197 |
| 2022 | 23 | 4,085 | 5,424 | $662,652 | $259,814 |
| 2021 | 22 | 4,619 | 6,222 | $505,437 | $298,410 |
| 2020 | 24 | 5,412 | 7,469 | $512,716 | $291,925 |
Total Patients
17,676
Total Services
23,702
Medicare Billing
$1.1M
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 562 | 752 | $188,752 | $60,036 | 31.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 303 | 311 | $120,668 | $38,551 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 146 | 172 | $60,372 | $21,678 | 35.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 116 | 117 | $44,343 | $15,030 | 33.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 64 | 145 | $33,785 | $12,994 | 38.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 86 | 96 | $32,544 | $12,470 | 38.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 102 | 102 | $33,354 | $11,477 | 34.4% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 55 | 55 | $31,075 | $10,990 | 35.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 785 | 1,117 | $58,084 | $10,258 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 193 | 197 | $34,869 | $8,080 | 23.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 141 | 147 | $20,826 | $7,411 | 35.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 85 | 144 | $22,608 | $6,730 | 29.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 491 | 628 | $10,048 | $3,829 | 38.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 50 | $7,750 | $2,983 | 38.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $6,630 | $2,549 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 32 | $6,080 | $2,200 | 36.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 79 | 81 | $3,321 | $1,243 | 37.4% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 13 | 13 | $3,302 | $1,018 | 30.8% |
| G0250 | Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | Office | 2023 | 17 | 143 | $2,431 | $877.27 | 36.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 79 | 81 | $2,187 | $822.12 | 37.6% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 15 | 15 | $2,145 | $722.15 | 33.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $3,300 | $589.02 | 17.8% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 59 | 59 | $1,416 | $547.36 | 38.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 17 | 30 | $1,740 | $528.76 | 30.4% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 24 | 25 | $2,025 | $305.36 | 15.1% |
About Dr. John Bartolozzi, MD
Dr. John Bartolozzi, MD is a Cardiovascular Disease healthcare provider based in Enid, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1366445876.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Bartolozzi, MD has received a total of $7,557 in payments from pharmaceutical and medical device companies, with $1,088 received in 2024. These payments were reported across 410 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($6,304).
As a Medicare-enrolled provider, Bartolozzi has provided services to 17,676 Medicare beneficiaries, totaling 23,702 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Enid, OK
- Active Since 05/30/2005
- Last Updated 10/08/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1366445876
Products in Payments
- Micra (Device) $1,637
- ELIQUIS (Drug) $635.44
- ENTRESTO (Drug) $544.17
- XARELTO (Drug) $523.09
- Corlanor (Drug) $488.68
- VERQUVO (Drug) $377.88
- Repatha (Biological) $313.64
- Kerendia (Drug) $289.32
- LEQVIO (Drug) $244.91
- JARDIANCE (Drug) $225.21
- BRILINTA (Drug) $213.68
- LifeVest (Device) $184.31
- SAMSCA (Drug) $168.37
- NORTHERA (Drug) $109.41
- Arcalyst (Drug) $104.39
- Xience Alpine cornary stent system (Device) $75.85
- Flexitouch Plus (Device) $69.52
- INJECTAFER (Drug) $67.07
- BYSTOLIC (Drug) $53.65
- MITRACLIP (Device) $41.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Enid
Nikunjkumar Patel, Md, MD
Cardiovascular Disease — Payments: $7,733
Cardiovascular Disease $7,733
John Schrader, M.d, M.D
Cardiovascular Disease — Payments: $7,630
Cardiovascular Disease $7,630
Douglas Brown, Md, MD
Cardiovascular Disease — Payments: $2,443
Cardiovascular Disease $2,443
Dr. Chander Malhotra, Md, MD
Cardiovascular Disease — Payments: $330.16
Cardiovascular Disease $330.16
Dr. Uma Guniganti, Md, MD
Cardiovascular Disease — Payments: $249.23
Cardiovascular Disease $249.23